Study Finds Imprimis’ Dropless Compounds Safe for Use in Cataract Surgery with Trabecular Microbypass Stents

June 1, 2018: By Jon Swedien

A recent study found Imprimis Pharmaceuticals’ Dropless formulations might be a safe option for glaucomatous eyes having cataract surgery with trabecular microbypass stent insertion, the San Diego company announced May 30.

The Imprimis Dropless formula is a single intraocular injection of triamcinolone and moxifloxacin (Tri-Moxi) or triamcinolone, moxifloxacin, and vancomycin (Tri-Moxi-Vanc).

Both formulations are designed to be administered during ocular surgery to replace or reduce the need for patient-administered antibiotic and anti-inflammation drops after surgery.

The Journal of Cataract and Refractive Surgery in January 2018 published a study of 483 eyes with glaucoma comparing the Dropless formulations with a standard drop regimen following surgery.

The study found that the Dropless formulations were similar to a standard drop regimen in terms of safety.

Imprimis CEO Mark Baum said the advantage of Dropless is doctors and patients don’t have to worry about a drop regime after surgery.

“This formulation continues to be an important option for patients and doctors alike, to help reduce or eliminate the need for post-surgery eye drop regimens and the potential for complications with medication adherence,” Baum said.

The study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of their cataract surgery.

To evaluate safety, the study recorded incidence of intraocular pressure (IOP) spikes, defined as an increase of at least 15 mmHg from baseline IOP. There was no statistically significant difference in the rate of IOP spikes between the two groups.

The safety profiles of both groups were also favorable. In the study group, there were no reported cases of inflammation, cystoid macular edema (CME), infection, or retinal detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023